Covid19 in India: Corona is wreaking havoc in many countries around the world, including China. A large number of people are dying due to Corona infection. At the same time, in India too, the government is very cautious after the case of Omicron’s BF.7 sub-variant came to light. The vaccination campaign in India continues continuously. Corona-related preparations are under review by the Central Government. The governments of many states, including Prime Minister Modi, are showing high alert about the new variant.
Due to the increasing number of corona patients, healthcare facilities in China have completely collapsed. At the same time, in view of the danger of new variants, the Government of India has issued several guidelines, including random sampling.
corona virus review
Prime Minister Modi held a high-level review meeting on December 22 on the corona infection situation in the country. The Union Health Ministry on Wednesday reviewed the Kovid-19 situation in India in view of the rise in corona cases in several other countries, including China and Japan. China is the only major country where cases have risen rapidly. In such a situation, it is important to consider whether India is safe from the factors that have wreaked havoc in China. Some analyzes suggest that India is better protected than China and that there is little chance of a China-like situation.
How threatening is Omicron’s BF.7 variant?
Omicron’s new BF.7 sub-variant, which is currently wreaking havoc in China, has been around in India for the past few months. The central government has also said that people should not be afraid of this. All 4 patients found to be infected with this variant in India have already recovered. Cases of infection with the new variant were reported in Gujarat and Odisha. VK Paul, head of the National Task Force on Covid-19 and a member of Niti Aayog, also says there is no need to panic. Enough tests are being done. India first detected the BF.7 sub-variant in a sample taken in July.
India Vaccines and Booster Doses
The vaccination campaign is continuously carried out in India. Booster doses are also being administered. Vaccines from India have also been shown in some studies to work better than those from China. However, better work is still needed regarding the booster dose. 96 percent of the Kovid-19 vaccines administered in India are Covishield and Covaxin prepared by Oxford or AstraZeneca. The vaccines that are administered in China are Coronavac and Sinopharm. The efficacy of the Oxford or AstraZeneca vaccine has been tested against CoronaVac. A study of one million people in Brazil found that both vaccines provided similar protection among the young, but that CoronaVac was less effective in the elderly.
Infection, Vaccination and Immunity
Like China, the infection is not spreading in India with Omicron’s BF.7 subvariant. Even expert doctors believe that this variant will be very less effective in India. Vaccination has happened faster in India than in China. In India, the effect of corona infection and the death rate also gradually decreased. China has yet to develop any kind of mRNA or adenoviral vaccine. Despite being behind in drivers, India has no chance of a wave like China. China’s strict lockdown also meant that fewer people in the country developed natural immunity to recent infections, while in India immunity went both ways.
read this too: Covid-19: ‘Corona variant XBB has no symptoms of cough and fever’, Ministry of Health told the truth of this viral message